Agreement expands Mycovia’s worldwide commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia will continue to quickly develop VT-1161 as a possible first FDA-approved remedy for recurrent candidiasis that is vulvovaginal
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a special permit and development and technology transfer contract with Gedeon Richter Plc., located in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, a dental antifungal item prospect, is in stage 3 medical studies when it comes to remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million ladies global every year.
“We are excited to partner with Gedeon Richter, a business with strong market leadership in women’s health, to produce and commercialize VT-1161, our possible first treatment that is FDA-approved RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. Continue reading “Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand”